Novel combination treatment for acute myeloid leukemia (AML)

Abstract

The invention relates to a pharmaceutical product comprising a) an inhibitor of the MDM2-p53 interaction as a first component; and b) cytarabine as a second component. The pharmaceutical product is used as a combined preparation for the sequential or simultaneous use in the treatment of cancer, particularly AML.

Description

Technical field [0001] The present invention relates to a combination therapy for the treatment of proliferative disorders, such as cancer, particularly acute myeloid leukemia (AML). More specifically, the present invention discloses a combination of the current main therapy for AML, the compound cytarabine (Ara-C), and a compound used as an inhibitor of MDM2-p53 interaction. It was surprisingly found that this combination exhibited an effect (synergism) greater than the additive effect. Background technique [0002] p53 is a tumor suppressor protein that plays a major role in preventing cancer. It protects cell integrity and prevents permanent damage to the clone's reproduction by inducing growth arrest or apoptosis. At the molecular level, p53 is a transcription factor that can activate a group of genes involved in the regulation of cell cycle and apoptosis. p53 is a powerful cell cycle inhibitor that is precisely regulated by MDM2 at the cellular level. MDM2 and p53 form a ...

AI Technical Summary

Problems solved by technology

For example, a molecular defect commonly found in the p16INK4 / p19ARF locus was shown to affect the degradation of the MDM2 protein

Images